Leiden University Medical Center
LUMC is a long established and modern university medical center with 7000 staff and focuses on top clinical and highly specialized care. This is backed up by top tier research groups including imaging and tumor immunology for which it has world renowned status. Translational research is at the heart of LUMC’s research strategy. Current science crosses traditional borders. Within LUMC different specialists work together around research themes. Combining cross-border expertise may solve biomedical problems and bring answers not found when working in a stand-alone fashion. LUMC focuses on 7 medical research profiles among which are “Cancer Pathogenesis and Therapy” and “Biomedical Imaging”.

Staff Expertise
  • The group of Professor Lowik is one of the leading molecular imaging groups in the world as it specialises in translating preclinical optical imaging techniques towards the use of fluorescence-based probes in surgery.
  • Image-Guided Surgery group headed by Dr. Vahrmeijer focuses on clinical studies on fluorescence image-guidance in cancer surgery. In clinical trials at the LUMC IGS has already been applied in over 300 patients. His current research focuses on the introduction of image-guided surgery using clinically available probes and on the clinical introduction of novel probes.
  • Professor Ossendorp investigates the behaviour of clinically active synthetic peptide vaccines in cancer patients through the use of imaging techniques. He uses a multidisciplinary approach to study the chemical, immunological and pharmaceutical aspects of tumor-specific vaccination in detail and he aims to bring cancer immunotherapy to a higher level.
  • They are all involved with training and mentoring young scientists and PhD students on a daily bases and have committed at least 10% of their time to this ITN described here
  • The LUMC PSs and CSs as well as the mentors that will be assigned to the ITN are all fully committed to spend their time on the project. Their respective postdocs and scientists will also be involved during the SECs that are hosted by the LUMC (the reasoning for those SECs is outlined in Table 19). All assigned staff members will support the SECs utilizing their respective skills such as testing out the PDX model, integrating optical and MRI moieties onto biomaterial carriers (SEC for ESR8), developing the constructs for WP3, working on different biomaterial-based particles or for the in vivo measurements. LUMC is also committed to contribute towards the training as described in TPs 1-4, specifically being the LP for workshops 1 and 5.

Key facilities and infrastructure
  • The labs of the respective research groups are fully equipped and staffed for in vivo non-invasive small animal imaging (Radiology) and brain analysis (Neurology and Human Genetics).
  • The imaging labs include a clinical intraoperative camera system (Artemis), various preclinical optical systems and three MRI systems including an ultra- high magnetic field (17.6 Tesla) instrument.

Previous involvement in Research and Training Programmes
  • 2000 EC FP5: Research Training Network; Neuronal Calcium channels in human disease
  • 2004 EC FP6: Lifesciences, Genomics & Biotechnology for Health
  • 2004 EC FP6: STREP; Migraine genes and neurobiological pathways (EUROHEAD)
  • 2004 EC FP6: European Molecular Imaging Labs (EMIL)
  • 2005 EC FP6: European network for research on Alternating Hemiplegia in Childhood for promoting SMEs integration
  • 2007 EC FP7: Diagnostic Molecular Imaging (DIMI)
  • 2008 EC FP7 European network for rare neurological diseases (nEUroped)
  • 2008 EU FP7: Targeting LRP5 to increase bone formation in osteoporosis
  • 2008 EU FP7: European Network for Cell Imaging and Tracking Expertise
  • 2010 – 2013: FP7-funded NIMBL grant “NIMBL—Nuclease Immune Mediated Brain and Lupus-like conditions

Current Involvement in Research and Training Programmes
  • Regional: ZonMw TOP - Antigen handling by dendritic cells (2012-2015)
  • 2013 - 2017: EU Marie Curie IAPP project, BRAINPATH
  • 2014 - 2018: EU Marie Curie RISE project, PRISAR

  • Kessler JH, Ossendorp F et al. Nat Immunol. 12, 45-53 (2011).
  • Snoeks TJ et al. Mol Imaging Biol 2014; 16:147-151.
  • Crus LJ et al. J Control Release 2014; 192:209-218.
  • Tummers QR et al. Int J Surg Case Rep. 2014; 6C:150-153.
  • Schaafma BE et al. J Surg Oncol. 2014; 7: 845-850.
  • Rosalia RA et al. Biomaterials 2015; 40: 88-97.

Overview of all participants ...